Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.85 |
| ▸ | LMNA | P02545 | 4/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27597233 | 0.92 | KMT2A (0.82) | TDP1KMT2ALMNAALDH1A1KDM4E | |
| SCHEMBL30335693 | 0.92 | KMT2A (0.82) | TDP1KMT2ALMNAALDH1A1KDM4E | |
| Benzyl Nicotinate SCHEMBL24600 | 0.92 | LMNA (1.00) | TDP1KMT2ALMNAALDH1A1KDM4E | |
| Benzyl Nicotinate SCHEMBL29394048 | 0.92 | LMNA (1.00) | TDP1KMT2ALMNAALDH1A1KDM4E | |
| SCHEMBL22946269 | 0.92 | KMT2A (0.88) | TDP1KMT2ALMNAALDH1A1KDM4E | |
| Benzyl Nicotinate SCHEMBL29080664 | 0.90 | LMNA (0.97) | TDP1KMT2ALMNAALDH1A1KDM4E | |
| Benzyl Nicotinate SCHEMBL28041943 | 0.90 | LMNA (0.97) | TDP1KMT2ALMNAALDH1A1KDM4E | |
| Benzyl Nicotinate SCHEMBL30432197 | 0.88 | TDP1 (0.91) | TDP1KMT2ALMNAALDH1A1KDM4E | |
| Benzyl Nicotinate SCHEMBL22654538 | 0.85 | LMNA (0.86) | TDP1KMT2ALMNAALDH1A1KDM4E | |
| SCHEMBL14937604 | 0.84 | KMT2A (0.76) | TDP1KMT2ALMNAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273480-A1 | INOSITOL NICOTINATE CRYSTALLINE FORM A AND PREPARATION METHOD THEREFOR | WEIFANG SHENGYU PHARMA CO., LTD. (CN) | 2018-09-27 | — | — | US | claimed |
| EP-3354642-A1 | INOSITOL NICOTINATE CRYSTALLINE FORM A AND PREPARATION METHOD THEREFOR | Weifang Shengyu Pharma Co., Ltd. (CN) | 2018-08-01 | — | — | EP | claimed |
| US-4115392-A | ANTI-HYPERLIPEMIC AGENT | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1978-09-19 | — | — | US | claimed |
| US-10370334-B2 | Inositol nicotinate crystalline form A and preparation method therefor | WEIFANG SHENGYU PHARMA CO., LTD. (CN) | 2019-08-06 | — | — | US | disclosed |
| US-20180273480-A1 | INOSITOL NICOTINATE CRYSTALLINE FORM A AND PREPARATION METHOD THEREFOR | WEIFANG SHENGYU PHARMA CO., LTD. (CN) | 2018-09-27 | — | — | US | disclosed |
| EP-3354642-A1 | INOSITOL NICOTINATE CRYSTALLINE FORM A AND PREPARATION METHOD THEREFOR | Weifang Shengyu Pharma Co., Ltd. (CN) | 2018-08-01 | — | — | EP | disclosed |
| EP-2427194-A1 | PYRROLIDINE-DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120053181-A1 | PYRROLIDINE-DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-03-01 | — | — | US | disclosed |
| EP-2276756-B1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2011-11-30 | — | — | EP | disclosed |
| WO-2011137054-A1 | NOVEL BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-11-03 | — | — | WO | disclosed |
| US-7902356-B2 | Thiazolopyridinone derivates as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2274296-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | disclosed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | disclosed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | disclosed |
| US-4795638-A | RUBEFACIENT, PLANT EXTRACT, POLYSILOXANE | L'OREAL (FR) | 1989-01-03 | — | — | US | disclosed |
| US-4115392-A | ANTI-HYPERLIPEMIC AGENT | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1978-09-19 | — | — | US | disclosed |
| US-4115392-A | ANTI-HYPERLIPEMIC AGENT | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1978-09-19 | — | — | US | disclosed |
| US-4115392-A | ANTI-HYPERLIPEMIC AGENT | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273480-A1 | INOSITOL NICOTINATE CRYSTALLINE FORM A AND PREPARATION METHOD THEREFOR | SLC5A11, ITPA, NAPRT | TDP1 3861/4885KMT2A 3013/4885LMNA 1416/4885 |
| US-10370334-B2 | Inositol nicotinate crystalline form A and preparation method therefor | SLC5A11, ITPA, NAPRT | TDP1 3861/4885KMT2A 3013/4885LMNA 1416/4885 |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | PNPO, NAMPT, NAPRT | TDP1 1717/4885KMT2A 2179/4885LMNA 3496/4885 |
| US-20120053181-A1 | PYRROLIDINE-DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | TDP1 3045/4885KMT2A 4134/4885LMNA 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.